KRAS G12D/V TCR-fusion protein therapy (Corregene)

N/A

Report date: 2023/12/26 13:48:49

Base Information

Drug NameKRAS G12D/V TCR-fusion protein therapy (Corregene)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionKRAS G12D inhibitorsKRAS G12V inhibitors
TargetsKRAS G12DKRAS G12V
Therapy Area/IndicationsPancreatic NeoplasmsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesCorregene Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCorregene Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A